Mouse Genome Informatics
ht
    Ttntm1Brge/Ttn+
B6.Cg-Ttntm1Brge
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
cardiovascular system
N
• under normal condition, mice exhibit normal cardiac function and mechanical properties (J:152736)
• after 2 weeks of treatment with angiotensin II, mice exhibit increased left ventricular end-diastolic diameter (LVEDD) compared with similarly treated wild-type mice
• however, a normal decrease in LVEDD a week after angiotensin II treatment is observed
• mice treated with angiotensin II or isoproterenol exhibit increased left ventricular dilation compared with similarly treated wild-type mice
• following treatment with angiotensin II or isoproterenol
• following treatment with angiotensin II or isoproterenol
• after 1 and 2 weeks of treatment with angiotensin II, mice exhibit decreased fractional shortening compared with similarly treated wild-type mice
• after treatment with isoproterenol, mice exhibit reduced ejection fraction and fractional shortening compared with similarly treated wild-type mice

homeostasis/metabolism
• following treatment with angiotensin II or isoproterenol
• mice treated with angiotensin II or isoproterenol exhibit left ventricular dilation, decreased fractional shortening, increased left ventricular end-diastolic diameter, and increased cardiac interstitial fibrosis compared with similarly treated wild-type mice

muscle
• following treatment with angiotensin II or isoproterenol
• after 1 and 2 weeks of treatment with angiotensin II, mice exhibit decreased fractional shortening compared with similarly treated wild-type mice
• after treatment with isoproterenol, mice exhibit reduced ejection fraction and fractional shortening compared with similarly treated wild-type mice

Mouse Models of Human Disease
OMIM IDRef(s)
Cardiomyopathy, Dilated, 1G; CMD1G 604145 J:152736